POLBF - Poolbeg Pharma's new VP of Clinical Operations Laura Maher aims to help progress development assets
(NewsDirect)
Poolbeg Pharma PLC's newly appointedVice President of Clinical Operations Laura Maher joinedProactive's Stephen Gunnion to discuss her role at thecompany.
Maher detailed herresponsibilities at Poolbeg, emphasising her leadership in developingand managing clinical programs. She highlighted the importance ofcollaborations, both internally and with external service providers,to ensure the acquisition of quality data.
Maher's significant achievements at Amryt include herpivotal role in the development and approval of Filsuvez, a treatmentfor Epidermolysis Bullosa (EB). She oversaw the largest-ever EB trial,leading to EMA approval in June 2022, marking it as the world’sfirst approved treatment for EB. Despite initial FDA rejection, herperseverance led to eventual FDA approval in December 2023.
Her extensive background in clinicalresearch and operations, beginning with a research master's degreeand experience in various roles across academia and smallpharmaceutical companies, informs her approach at Poolbeg. Maherexpressed her enthusiasm for working in a dynamic environment likePoolbeg, particularly excited about their cancer immunotherapy andcytokine release syndrome projects.
ContactDetails
Proactive UK Ltd
+44 20 7989 0813
Copyright (c) 2024 TheNewswire - All rights reserved.